* Cel-Sci Corp., of Alexandria, Va., signed a cooperative researchand development agreement with the Naval Medical ResearchInstitute of the U.S. Navy to develop a malaria vaccine. They willmake use of Cel-Sci's heteroconjugate technology that combines Tcell-binding ligands with small, disease-associated peptide antigens.
* Immunex Corp., of Seattle, said an FDA advisory committee willreview Novantrone (mitoxantrone) for advanced prostate cancer onSept. 11, 1996. Novantrone already is approved for use in acute non-lymphocytic leukemia.
* Isis Pharmaceuticals Inc., of Carlsbad, Calif., revised its agreementwith Eisai Co. Ltd., of Tokyo, concerning fomivirsen (ISIS 2922), anantisense compound in Phase III trials for cytomegalovirus retinitis inAIDS patients. Isis will assume full control of continued developmentand commercialization, while Eisai will get royalties on sales. Thecompanies had shared all rights in the U.S. and Europe. Specificterms of the new deal were not disclosed.
* NeoPharm Inc., of Lake Forest, Ill., said its board approved a 2-for-1 stock split for stockholders of record on Aug. 26, 1996. Thecompany (NASDAQ:NPRM), developing cancer drugs, went publicin January 1996 at $7 and closed at $14 on Aug. 13, 1996.
* Protein Polymer Technologies Inc., of San Diego, said it raisedmore than $800,000 from the exercisement of warrants from holdersof Series B preferred stock. The holders acquired 322,663 shares ofunregistered stock.
* Techniclone International Corp., of Tustin, Calif., has retainedFinancial Relations Board Inc. to handle outside investor relations.
* Vertex Pharmaceuticals Inc., of Cambridge, Mass., saidunderwriters of its recent public offering exercised their option on anadditional 450,000 shares, bringing the total offering to 3.45 millionshares at $24 each. Gross proceeds will be about $83 million with anet to Vertex of $77.5 million. (See BioWorld Today, Aug. 12, 1996,p. 1.)
(c) 1997 American Health Consultants. All rights reserved.